A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...